IQVIA vs Medidata (2026)
The two largest platform vendors in clinical development, both now selling agents, and both indexed for the AI layer rather than for the underlying business. IQVIA launched a unified agentic platform and marketplace in March 2026 spanning clinical, commercial and real world evidence work, names its infrastructure stack with unusual precision, and has the most developed governance apparatus in this category. Medidata's capabilities sit on a trial platform spanning tens of thousands of studies with the most complete security disclosure located anywhere in this index. For a sponsor the practical question is rarely which agents are better; it is which platform already holds your studies, because adding capability inside a validated environment is a far shorter path than qualifying a new one. Both should be asked to state plainly which of their several relationships to your data governs which capability.
- The platform launched in March 2026 spans clinical, commercial and real world evidence operations with an agent marketplace, and adoption breadth is specific rather than aspirational.
- The infrastructure stack is named with unusual precision for a company this size, which lets a buyer reason about what the agents are actually built on.
- The governance apparatus is the most developed in this category and includes a concrete architectural control rather than a principles page.
- The AI capabilities sit on a platform spanning tens of thousands of studies and millions of patients, which is the asset the agents are built on and is not replicable.
- The security disclosure for the underlying platform is the most complete located anywhere in this index, which matters for a system holding trial data at that scale.
- For a sponsor already running the platform, adding capability inside a validated environment avoids the revalidation questions a new system triggers.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. IQVIA and Medidata are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | IQVIA | Medidata |
|---|---|---|
| Primary category | Clinical Trials AI | Clinical Trials AI |
| Headquarters | Research Triangle Park, North Carolina | New York, New York |
| Website | iqvia.com | medidata.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index records no top capability grade for IQVIA on any axis it scores. Set against Medidata, IQVIA grades higher on Model and Technology Transparency and AI Governance and Bias Disclosure. Its thinnest published disclosure sits on AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Medidata its top capability grade on several axes, including Security Certifications and Trust Center, FDA and Regulatory Status and EHR and Interoperability Depth. Set against IQVIA, Medidata grades higher on several axes, including HIPAA and BAA Posture, Security Certifications and Trust Center and FDA and Regulatory Status. Its thinnest published disclosure sits on AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose IQVIA or Medidata?
On the axes where the AI Health Index separates them, IQVIA grades higher on Model and Technology Transparency and AI Governance and Bias Disclosure, and Medidata grades higher on several axes, including HIPAA and BAA Posture, Security Certifications and Trust Center and FDA and Regulatory Status. Medidata leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do IQVIA and Medidata differ most?
The widest separation the AI Health Index records between IQVIA and Medidata is on Security Certifications and Trust Center, where IQVIA grades C and Medidata grades A. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.
Where do IQVIA and Medidata grade the same?
The AI Health Index grades IQVIA and Medidata the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model Supply Chain Disclosure. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have IQVIA and Medidata not disclosed?
At the last review, at least one of IQVIA and Medidata published thin or absent detail on AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Trials AI page.
Both companies stand in more than one relationship to health data, as service provider, data holder and software vendor, and neither states plainly which relationship governs which capability, which is the first thing a sponsor's legal team will ask. Neither publishes an attestation scoped to the agent platform specifically, as distinct from the wider business. IQVIA writes about oversight more than most vendors here and does not state what any specific agent decides on its own. Medidata's AI capabilities are named rather than described, with no published oversight design. Neither publishes pricing, and both are typically bundled into larger enterprise agreements.